T 1500 rpm for 6 min at 4 , washed twice with 2 mL PBS + 2 BSA, and resuspended in 50 of PBS + 2 BSA solution for blocking. Antibodies were added to corresponding tubes and incubated in the dark at 4 for 45 min. Cells were removed from incubation, washed again twice with PBS + 2 BSA, and resuspended in PBS containing 0.5 formaldehyde. Cell populations were gated on a minimum of 250,000 ce
T 1500 rpm for 6 min at 4 , washed twice with 2 mL PBS + 2 BSA, and resuspended in 50 of PBS + 2 BSA solution for blocking. Antibodies were added to corresponding tubes and incubated in the dark at 4 for 45 min. Cells were removed from incubation, washed again twice with PBS + 2 BSA, and resuspended in PBS containing 0.5 formaldehyde. Cell populations were gated on a minimum of 250,000 ce
Point-of-care assay, would capture most individuals without virological failure, for whom switching could be premature and unnecessary.ROC area under the curve for CD4 predicting VL,400 copies/ml0.91**0.0.0.90 p = 0.81,Patients monitored clinically with 12-weekly CD4 but no VL results1656 LCM participants initiated ART with median(IQR) CD4 86(32?40) cells/mm3 and were clinically monitored together
And clinical failure criteria, they were counted as immunological failures. Where CDM participants had both WHO 4 and WHO 3 events, they were counted as WHO 4 failures. Categorical variables were compared using chi-squared/exact tests, continuous variables using t-tests/rank-sum tests. To inform clinical practice when `tiebreaker' VL tests are not available to confirm that clinical/immunological f
And clinical failure criteria, they were counted as immunological failures. Where CDM participants had both WHO 4 and WHO 3 events, they were counted as WHO 4 failures. Categorical variables were compared using chi-squared/exact tests, continuous variables using t-tests/rank-sum tests. To inform clinical practice when `tiebreaker' VL tests are not available to confirm that clinical/immunological f
And clinical failure criteria, they were counted as immunological failures. Where CDM participants had both WHO 4 and WHO 3 events, they were counted as WHO 4 failures. Categorical variables were compared using chi-squared/exact tests, continuous variables using t-tests/rank-sum tests. To inform clinical practice when `tiebreaker' VL tests are not available to confirm that clinical/immunological f
S did not count as first-line failures. The decision to switch to a second-line bPI-containing regimen for first-line failure was based on clinical criteria in both groups (new/ recurrent WHO 4 event (per-protocol); or single or multiple WHO 3 events at clinician discretion), or confirmed CD4,100 cells/ mm3 on ART (,50 cells/mm3 before July 2006) for LCM. Switching was discouraged before 48 weeks
S did not count as first-line failures. The decision to switch to a second-line bPI-containing regimen for first-line failure was based on clinical criteria in both groups (new/ recurrent WHO 4 event (per-protocol); or single or multiple WHO 3 events at clinician discretion), or confirmed CD4,100 cells/ mm3 on ART (,50 cells/mm3 before July 2006) for LCM. Switching was discouraged before 48 weeks